





	Salcs (\$MN)	Share	Growth
U.S. Specialty Market	92,216	100.0%	7.69
Oncology	27,878	30.2%	9.29
Autoimmune	17,861	19.4%	18.09
HIV Antivirals	12,365	13.4%	10.09
Multiple Sclerosis	9,683	10.5%	10.69
Hematopoletic Growth Factors	4,714	5.1%	3.29
Erythropoietin Products	4,151	4.5%	-0.6%
Other Immunosuppressants	2,320	2.5%	3.39
Viral Hepatitis Products	1,936	2.1%	-33.59
Polyval immunogloblulins IV IN	Л 1,894	2.1%	-3.09
Growth Hormones	1,618	1.8%	5.8%
Top 10	84,421	91.5%	8.29
































## **Planning Infrastructure**

## Step 1: Establish the Business Planning Committee

 Include administrative sponsor, pharmacy leadership, key specialty medical staff leadership, contracting and finance

#### Step 2: Perform an internal and external situational analysis

- · Visit other programs
- Meet with oncology, GI, rheumatology, neurology, hepatology & other clinic staff to determine current hub & referral systems being utilized and the unmet need for coordinated care
- Meet with contracting department to determine price pressure placed by payers on clinic administered drugs & specialty pharmaceuticals

MUHC

# Planning Infrastructure

# Step 3: Determine your current state and any additional revenue opportunities

- Determine the number of Rx's generated and estimate the revenue impact
- Consultants are available to assist Visante, Therigy, D2 Consulting
- · Perform an analysis of 340B impact
  - · Review number of clinics listed as child sites for 340B
- · Perform an analysis of payer mix in each clinic

Payer	Percent Payer Mix(%)										
	MS	Rheum	GI	Нер	SOT	ONC	HIV/ID	CF	Endocrin	Neph	PH
BCBS	42.6	28.3	29.2	15.9	20.0	30.6	22.1	22.2	24.9	12.7	32.6
Commercial	1.7	0.4	0.5	0.7	0.8	0.8	2.1	0.4	0.8	0.6	0.7
HMO/PPO	21.8	15.0	18.9	8.9	8.0	11.2	13.8	13.0	12.9	7.4	19.3
Medicaid	8.9	16.2	10.1	30.2	20.2	15.9	28.0	16.5	15.6	12.8	7.3
Medicare	23.3	36.2	34.5	38.3	48.7	38.7	31.0	44.1	40.6	57.0	32.2
Self Pay	1.7	3.9	6.8	6.0	2.3	2.8	3.0	3.8	5.2	9.5	7.9

MIIIIC

## **Planning Infrastructure**

# Step 4: Determine what is required to establish a SP program in your institution

- Current retail pharmacy structure & services
  - Prepare a list of support services (benefits investigation, PA, PAP, billing & collection, call center, and case management)
  - Prepare a list of fulfillment services (drug access, payer contracts, marketing materials, care coordination, delivery, REMS, prescription renewal)
  - Determine if information systems and facilities are adequate
- Explore accreditation requirements for managed care contracting
- Determine if you have adequate management, clinical & support personnel

**DUH** 

## **Planning Infrastructure**

## Step 5: Develop a Marketing Plan

- · Define your target market
  - Orals and self-administered injectables vs. infusion
- · Medicare Part D open access
- Medicaid
- · Access PSAO contracts
- Determine top insurers & assess specialty network (Chicago)
  - PPO market BCBS (80%) & Aetna (11%)
  - HMO market BCBS (88%) & Humana (8%)
  - POS market United Healthcare (64%) & Cigna (35%)
- Determine key employers (Chicago & Suburbs)
- US GovernmentChicago Public Schools & City of Chicago
- Archers Daniel Midland
   Boeing
- Cook County
- Walgreen Co.
- Advocate healthcare
- Caterpillar

JUH

## Planning Infrastructure

## Step 6: Develop a Financial Proforma

- · Gross profit analysis by clinic
- Investigate Hep C opportunity

		FYS4		FYES		FWMF	
Revenue							
Gross Nevenue - Rheumatology/Gr	5	1,999,020	5	4,674,270	5	5,774,090	
Gross Revenue - Multiple Sclerosis	5	1,022,256	5	4,344,588	5	5,366,845	
Gross Revenue - Gi/Hepitology	5	303.103	5	1.285.189	5	1.591.293	
Gross Revenue Hem One Ingremental			s	481,600	S	963,200	
Gross Revenue - Solid Organ Transplant			5	441,054	5	4,410,536	
Scoss Revenue - HTV			5	-	5	9,957,929	
Casos Rauneur - Caso Management Fines			\$	21,667	6	53,60	
sad prot	8	(46,504)	8	(225/027)	8	(4,60,669	
Tutal Net Revenue	\$	2,176,681	4	11,026,140	8	21,086,618	
Total COSS	5	1,154,298	5	5,818,606	5	13,665,668	
SRO33 MARSIN	5	1,222,586	5	5,207,734	5	7,590,940	
Expenses							
Labor and Denefits	5	503,019	5	1,003,612	5	1,370,315	
Other Oxpenses	5	170,611	5	507,167	5	1,013,175	
Total Ofrect and indirect Expenses	5	674,430	5	1,590,779	5	2,383,495	
CASH FLOW OPCRATIONS	5	50,955	5	1,616,955	5	5,007,458	
CLIMILITATIVE CASH FLOW OPERATIONS	5	547,455	5	4,164,911	5	9,177,368	
CAPITAL			4	(24,000)			


MUHC

## Planning Infrastructure

## Step 7: Initiate program

- Determine scope # of specialty clinics included
- Allocate space & equipment
- · Determine if start-up consulting is needed
- Hire manager, clinical & support staff
- Determine what additional IT support systems are needed
- Send staff for training to another specialty program
- Prepare policies & procedures
- Develop case management protocols
- Meet with PhRMA learn about programs & hub requirements for patient assistance programs
- Kick off meetings with specialty clinic business staff, nursing & medical staff leadership – determine workflow in the clinic & how pharmacy will fit in.

JUHC



# Which of the following systems infrastructure is not to operate a specialty pharmacy? A. Case Management System B. Separate retail facility C. Clinical Staff D. Call Center

## Summary

- Determine what is the single most important aspect of your business plan
- Identify members of your organization that will need to be convinced seek alignment of stakeholders
- Ask finance to prepare the financials in the manner they are accustomed to using.
- If a quick start is needed, consider consultants
- Hire a manager with ambulatory care and contracting experience
- Place clinical staff in the clinics to capture referrals.

JUHC

# What's So *Special* About Specialty Pharmacies?

Overview and role of pharmacists and pharmacy technicians

Huda-Marie Kuttab, Pharm. D., BCPS Rush University Medical Center Clinical Pharmacy Specialist Specialty Pharmacy

# Disclosure

• I have no conflict of interest in relation to this activity.

# Objective

• Explain the role of a pharmacist and pharmacy technician in specialty pharmacy.

# **Specialty Pharmacy Mission**

- To provide medication management services to patients with chronic diseases
- To provide patient case management and high touch services to patients requiring complex therapies

# The Players

- Patient
- Provider
- Payors
- Pharmacists
- Pharmacy technicians

# Core services - Pharmacist

- Clinical assessments
  - Order accuracy
  - Baseline labs
  - Drug-drug interactions
  - Drug-disease interactions



# Core services - Pharmacist

- Benefits investigation
  - Ensure access
  - Prior authorizations
  - Medical necessity letters
  - Peer to peer reviews
- Patient education
- Injection training
- Medication education
- Disease state education



# Core services - Pharmacist

- Ongoing assessments
- Adverse effect management
- Therapy adjustment
- Medication adherence
- Re-education

# **Audience Question**

Which of the following does NOT describe a potential role of a specialty pharmacist?

- A. Recommending the titration of an interferon to minimize flu-like symptoms.
- B. Completing a peer-to-peer review to resolve the denial of a medication.
- C. Treating active tuberculosis prior to initiation of a TNF-alpha blocker.
- D. Recommending influenza vaccination prior to initiation of TNF-alpha blocker.

# Core services - Pharmacy Tech

- New patient enrollment
  - · Patient entry
- Benefits Investigation
  - Perform insurance verification
  - Initiate prior authorizations
  - Obtain financial assistance
  - Patient assistance programs


# Core services - Pharmacy Tech


- Prescription management
  - Order Processing
  - Packaging
  - Delivery
- Refill Management
- Manage calendars
- Reminder calls



# **Patient Case**

Ashley is a 29 year old female with a PMH of Crohn's Disease. Based on her risk factors for a severe disease course, it is decided to start biologic therapy with Humira® (adalimumab).





# Questions?

Hudamarie\_Kuttab@rush.edu